Users can access data about cancer statistics in the United States including but not limited to searches by type of cancer and race, sex, ethnicity, age at diagnosis, and age at death. Background Surveillance Epidemiology and End Results (SEER) database’s mission is to provide information on cancer statistics to help reduce the burden of disease in the U.S. population. The SEER database is a project to the National Cancer Institute. The SEER database collects information on incidence, prevalence, and survival from specific geographic areas representing 28 percent of the United States population. User functionality Users can access a variety of reso urces. Cancer Stat Fact Sheets allow users to look at summaries of statistics by major cancer type. Cancer Statistic Reviews are available from 1975-2008 in table format. Users are also able to build their own tables and graphs using Fast Stats. The Cancer Query system provides more flexibility and a larger set of cancer statistics than F ast Stats but requires more input from the user. State Cancer Profiles include dynamic maps and graphs enabling the investigation of cancer trends at the county, state, and national levels. SEER research data files and SEER*Stat software are available to download through your Internet connection (SEER*Stat’s client-server mode) or via discs shipped directly to you. A signed data agreement form is required to access the SEER data Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available under “Data Documentation and Variable Recodes”.

SEER collects cancer incidence data from population-based cancer registries covering approximately 47.9 percent of the U.S. population. The SEER registries collect data on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment, and they follow up with patients for vital status.There are two data products available: SEER Research and SEER Research Plus. This was motivated because of concerns about the increasing risk of re-identifiability of individuals. The Research Plus databases require more rigorous process for access that includes user authentication through Institutional Account or multiple-step request process for Non-Institutional users.

This dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumor size, examined regional LNs, regional positive LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.

The Surveillance, Epidemiology, and End Results (SEER) Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS).

This dataset contains Cancer Incidence data for Lung Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Flat file of United States County-level cancer incidence rates obtained from: https://www.statecancerprofiles.cancer.gov/incidencerates/ All data housed on that website are extracts from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program with rates computed using SEER*Stat as documented in the About section of the above website.

NA- not assessed/availablelcSSc- limited cutaneous systemic sclerosisdcSSc- diffuse cutaneous systemic sclerosisSSc/PPM- Systemic sclerosis and polymyositis overlapACA- anticentromere antibodySCL-70- anti-SCL 70 antibodyRNA Pol- anti-RNA polymerase III antibody* SCL-70 not assessedDemographics, smoking history and SSc subtype and serology.

The total assets of Seer with headquarters in the United States amounted to 436.27 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 6.05 million U.S. dollars. The trend from 2020 to 2023 shows, however, that this decrease did not happen continuously.

Rate: Number of new cases of breast cancer (per 100,000) diagnosed at the regional or distant stage among females.

Definition: Age-adjusted incidence rate of invasive breast cancer per 100,000 female population.

Data Sources:

(1) NJ State Cancer Registry, Dec 31, 2015 Analytic File, using NCI SEER*Stat ver 8.2.1 (www.seer.cancer.gov/seerstat)

(2) NJ population estimates as calculated by the NCI's SEER Program, released January 2015, http://www.seer.cancer.gov/popdata/download.html.

Data support a paper of this title:

A Geotemporospatial and Causal Inference Epidemiological Exploration of Substance and Cannabinoid Exposure as Drivers of Rising US Pediatric Cancer Rates

Data represent a compilation of various data inputs from numerous sources including the National Cancer Institute SEER*Stat National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Database, 2019 submission (2001-2017), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2020. Available at www.cdc.gov/cancer/public-use program; the National survey of Drug Use and Health conducted by the Substance Abuse and Mental Health Services Administration; and the US Census bureau.

Data also include inverse probability weights for cannabis exposure.

Data also include their geospatial linkage network constructed for all US states which makes Alaska and Hawaii spatially connected to the contiguous USA.

Data also include the R script used to conduct and prepare the analysis.

The total equity of Seer with headquarters in the United States amounted to 396.9 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 309.22 million U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.

SEER cancer incidence per 100,000 and percent contribution, 2008–2012a.

Clinical and pathological data of CRCLM patients who underwent primary tumor resection and chemotherapy from 2010 to 2015 were extracted from the SEER 8 registries database (SEER*Stat 8.4.3). A total of 3252 cases met the inclusion and exclusion criteria. Continuous variables were converted to categorical variables using X-tile software, which also determined optimal cutoff values for grouping. Patients were randomly divided into a training cohort (n=2276) and a validation cohort (n=976) in a 7:3 ratio.

The operating profit of Seer with headquarters in the United States amounted to -103.46 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 69.81 million U.S. dollars. The trend from 2020 to 2023 shows, furthermore, that this decrease happened continuously.

The liabilities of Seer with headquarters in the United States amounted to 39.36 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total increase by approximately 28.65 million U.S. dollars. The trend from 2020 to 2023 shows, however, that this increase did not happen continuously.

Clinical and pathological data of CRCLM patients who underwent primary tumor resection and chemotherapy from 2010 to 2015 were extracted from the SEER 8 registries database (SEER*Stat 8.4.3). A total of 3252 cases met the inclusion and exclusion criteria. Continuous variables were converted to categorical variables using X-tile software, which also determined optimal cutoff values for grouping. Patients were randomly divided into a training cohort (n=2276) and a validation cohort (n=976) in a 7:3 ratio.

The net cash of Seer with headquarters in the United States amounted to -59.06 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 38.23 million U.S. dollars. The trend from 2020 to 2023 shows, however, that this decrease did not happen continuously.

The net income of Seer with headquarters in the United States amounted to -92.97 million U.S. dollars in 2022. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 60.19 million U.S. dollars. The trend from 2020 to 2022 shows, furthermore, that this decrease happened continuously.

Mortality rates were calculated as defined in the text.Summary statistics for White cervical cancer mortality rates in 13 U.S. states from 1975 to 2010.

The revenue of Seer with headquarters in the United States amounted to 16.7 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total increase by approximately 16 million U.S. dollars. The trend from 2020 to 2023 shows, furthermore, that this increase happened continuously.